Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6778018 | 1.00 | CYP2D6 (0.46) | CYP2D6MEN1KMT2AALDH1A1CHRM2 | |
| SCHEMBL4358622 | 0.83 | MEN1 (0.54) | CYP2D6MEN1KMT2AALDH1A1CHRM2 | |
| SCHEMBL20169575 | 0.75 | MEN1 (0.47) | CYP2D6MEN1KMT2AALDH1A1CHRM2 | |
| SCHEMBL6778656 | 0.74 | MEN1 (0.39) | CYP2D6MEN1KMT2AALDH1A1CHRM2 | |
| SCHEMBL6778655 | 0.74 | MEN1 (0.39) | CYP2D6MEN1KMT2AALDH1A1CHRM2 | |
| SCHEMBL4366002 | 0.74 | ALDH1A1 (0.49) | CYP2D6MEN1KMT2AALDH1A1CHRM2 | |
| SCHEMBL22615820 | 0.73 | CHRM2 (0.42) | CYP2D6MEN1KMT2AALDH1A1CHRM2 | |
| SCHEMBL8324814 | 0.73 | CHRM1 (0.34) | CYP2D6MEN1KMT2AALDH1A1CHRM2 | |
| SCHEMBL22615861 | 0.72 | CHRM2 (0.41) | CYP2D6MEN1KMT2AALDH1A1CHRM2 | |
| SCHEMBL20031091 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699870-B2 | Phthalazine compounds and therapeutic agents for erectile dysfunction | EISAI CO., LTD. (JP) | 2004-03-02 | — | — | US | disclosed |
| US-20030105074-A1 | Phthalazine compounds and therapeutic agents for erectile dysfunction | EISAI CO., LTD. | 2003-06-05 | — | — | US | disclosed |
| US-6498159-B1 | SUCH AS 4-((3-CHLORO-4-METHOXYBENZYL)AMINO)-1-((4-HYDROXY-4 -HYDROXYMETHYL)PIPERIDINO)-6-PHTHALAZINE CARBONITRILE | EISAI CO., LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| EP-1057819-A1 | PHTHALAZINE DERIVATIVES AND REMEDIES FOR ERECTILE DYSFUNCTION | Eisai Co., Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105074-A1 | Phthalazine compounds and therapeutic agents for erectile dysfunction | CLIC1, CBR1, CBR3 | CYP2D6 2072/4885MEN1 1834/4885KMT2A 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.